Biogen Inc.’s stock BIIB rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval to Leqembi, the company’s Alzheimer’s disease treatment co-developed with Eisai Co. Ltd.
The step secures Medicare reimbursement for the first drug shown to slow the progress of the disease, rather than just treating its symptoms. The drug’s label will have a boxed warning about amyloid-related imaging abnormalities, or ARIA, which usually have no symptoms but in some rare cases cause life-threatening brain swelling, the FDA said Thursday. Oppenheimer reiterated... Biogen Inc.’s stock BIIB rose about 2% before paring those gains premarket Friday, after the U.S.
The step secures Medicare reimbursement for the first drug shown to slow the progress of the disease, rather than just treating its symptoms. The drug’s label will have a boxed warning about amyloid-related imaging abnormalities, or ARIA, which usually have no symptoms but in some rare cases cause life-threatening brain swelling, the FDA said Thursday.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »